中国麻风皮肤病杂志 ›› 2025, Vol. 41 ›› Issue (11): 821-823.doi: 10.12144/zgmfskin202511821

• 病例报告 • 上一篇    下一篇

度普利尤单抗治疗特应性皮炎合并瘢痕疙瘩一例

魏艳杰1,2,任汝姣1,2,张鲁1,2,张佩莲1,2   

  1. 1 云南中医药大学第一附属医院，云南昆明，650021; 2 云南省中医医院皮肤科，云南昆明，650021
  • 出版日期:2025-11-15 发布日期:2025-11-11

Dupilumab in the treatment of atopic dermatitis complicated by keloid: a case report

WEI Yanjie1,2, REN Rujiao1,2, ZHANG Lu1,2, ZHANG Peilian1,2   

  1. 1 Department of Dermatology, The First Affiliated Hospital of Yunnan University of Traditional Chinese Medicine, Kunming 650021, China; 2 Department of Dermatology, Yunnan Provincial Hospital of Traditional Chinese Medicine, Kunming 650021, China
  • Online:2025-11-15 Published:2025-11-11

PDF (PC)

34

摘要： 有文献报道特应性皮炎（atopic dermatitis，AD）是瘢痕疙瘩（keloid，KD）的独立危险因素， AD与 Th2 轴的关联可能增加KD发生的风险。度普利尤单抗治疗KD虽未列入说明书及指南，但已有其治疗KD有效的报道。本例是国内首次报道的度普利尤单抗治疗KD的患者。患者重度特应性皮炎5年，KD 14年。AD常规治疗效果不佳，给予度普利尤单抗标准剂量规律治疗，治疗10周后，AD皮损基本消退，留有色素沉着，KD红斑、硬度及高度均有改善，小瘢痕基本消退。随访1个月，AD未复发，KD稳定。

关键词: 度普利尤单抗, 特应性皮炎, 瘢痕疙瘩

Abstract: It has been reported in the literature that atopic dermatitis (AD) is an independent risk factor for keloid (KD), and the association between AD and the Th2 axis may increase the risk of KD development. Although dupilumabits for KD is not included in the prescribing information or guidelines, there have been reports of its efficacy in treating KD. This case represents the first reported instance of dupilumab treatment for KD in China. The patient had a 5-year history of severe atopic dermatitis and a 14-year history of keloids. Conventional treatments for AD yielded suboptimal results, and the patient was subsequently administered standard-dose dupilumab at regular intervals. After 10 weeks of treatment, the AD lesions had largely resolved with residual hyperpigmentation, while the erythema, hardness, and height of the KD showed improvement, with smaller keloids nearly resolved. At the one-month follow-up, there was no recurrence of AD, and the KD remained stable.

Key words: dupilumab, atopic dermatitis, keloid